Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.

Fraz?o JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000 Sep; 36(3):550-61.

View in: PubMed

subject areas

Adult
Aged
Alkaline Phosphatase
Calcium
Double-Blind Method
Drug Administration Schedule
Ergocalciferols
Female
Humans
Hyperparathyroidism, Secondary
Male
Middle Aged
Parathyroid Hormone
Phosphorus

authors with profiles

Keith Norris

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support